Premium
Dynamic 3d‐mr mammography: Is there a benefit of sophisticated evaluation of enhancement curves for clinical routine?
Author(s) -
MüllerSchimpfle Markus,
Ohmenhäuser Katja,
Sand Jürgen,
Stoll Peter,
Claussen Claus D.
Publication year - 1997
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880070137
Subject(s) - medicine , pharmacokinetics , nuclear medicine , mammography , breast cancer , cancer
Abstract The purpose of the study was to compare standard analysis with pharmacokinetic analysis of time‐intensity curves in dynamic three‐dimensional (3D) MR mammography (MRM) for their capability of differentiating benign from malignant disease. Dynamic MRM of the whole breast was performed at 1.0 T using an axial fast low‐angle shot (FLASH) 3D sequence. For the standard evaluation, the enhancement of the first minute ( E 1 ) and the slope of enhancement from minute 2 to 10 (SE 2–10 ) were calculated. For pharmacokinetic analysis, the amplitude of enhancement ( A ), distribution time ( t 21 ), and elimination time ( t el ) were computed. Sixty‐two histologically verified lesions were evaluated. The standard evaluation methods yielded a highly significant difference between benign and malignant disease for E 1 ( P = .0008) and SE 2–10 ( P = .0001). The pharmacokinetic parameters gained similarly significant P values ( A, P = .0014; t 21 , P = .0024; t el , P = .0001). Both standard and pharmacokinetic analysis concordantly discriminated between benign and malignant lesions in discriminant analysis. Compared with standard analysis, a pharmacokinetic analysis of time‐intensity curves is not beneficial for routine clinical diagnosis.